SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull Corp ($BULL) is trending amid intense community debate, largely driven by ongoing price depreciation attributed to tax loss harvesting and persistent selling pressure from SPAC-related share overhang. Despite recent inclusion in the Russell 2000/3000 indexes and reported strong revenue growth in its latest quarter, sentiment remains highly polarized. Bulls view the stock as deeply undervalued with significant long-term potential from user growth and international expansion, while bears warn of continued dilution and question the company's valuation.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after receiving FDA approval for NEREUS (tradipitant), hailed as the first new motion sickness drug in over 40 years. The community is buzzing about its substantial potential to address GLP-1 induced nausea and vomiting, viewing this as a significant market expansion that could drive a revaluation of the company. With additional pipeline catalysts anticipated, many are expressing strong conviction in its future growth, despite some predicting immediate profit-taking.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amid sharp investor division, primarily driven by the recent FDA approval of Novo Nordisk's oral Wegovy pill and speculation around potential distribution partnerships for GLP-1 treatments. While many note the stock's significant drawdown and high short interest as bearish indicators, others view the current valuation as a prime long-term buying opportunity, citing strong fundamentals, institutional accumulation, and the company's expansion into new health verticals and international markets. The community is actively debating whether the current dip sets the stage for a short squeeze or further decline for the direct-to-consumer telehealth provider.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is actively debated amid its significant price volatility, with many investors anticipating potential breakthroughs and new partnerships at the upcoming CES 2026. While some highlight its robust contractual backlog, growing revenues in voice AI, and debt-free status as a compelling buying opportunity, others express deep skepticism regarding management's communication and the stock's recent performance.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is currently trending amidst significant investor frustration as its stock repeatedly hits new all-time lows, fueling widespread community debate over perceived management effectiveness and production execution. Despite recent accolades for its Gravity SUV and strategic partnerships, conversation is heavily focused on the extended interim CEO tenure, potential dilution, and critical concerns about meeting annual vehicle production targets compared to surging EV competitors.

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

Ekso Bionics Holdings is capturing market attention following a proposed business combination with Applied Digital, which would see Applied Digital's cloud GPU business spun off into ChronoScale, an AI compute platform. The potential "AI merger" is fueling fervent discussion among traders, with many anticipating a significant run due to the stock's low float, while others express concerns about potential shareholder dilution.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending amid choppy, low-volume trading as market participants grapple with mixed signals from recent Fed minutes regarding future rate policy. Community discussions are sharply divided, with bulls anticipating continued strength towards new highs and bears predicting an imminent correction, particularly as the anticipated "Santa Rally" appears to be largely absent.

Featured in Matt Furies latest book Cortex Vortex as Ratos nemesis. The character is also part of ZOGZ which confirms its real name.  Matt Furie, the artist best known for creating Pepe the Frog, has been working on a new book. The news comes from his editor, who goes by the handle @beuys_on_sale_ on Instagram. In a recent post, the editor hinted at an upcoming project featuring new characters named Gasspas and Rato. Gasspas’s visual appearance can be inferred from the artwork. In one illustration, Gasspas is depicted looming over two rats (Rato and Wat), gazing down at them in a menacing way (an image that has circulated among collectors). This inferred that Gasspas is Ratos nemesis in the new book Cortex Vortex reinforced by community quips that “cats eat rats”. Gasspas debuted as part of ZOGZ, a collection of 111 original NFT character illustrations by Matt Furie launched in May 2023.

Gasspas

Gasspas ($GASS) is currently a hot topic among crypto communities, with many drawing parallels to early Pepe and some associating it with creator Matt Furie. Enthusiasts are actively accumulating due to its low market capitalization, anticipating significant price movements and aiming to 'drop a zero' in its value as part of a broader meme coin rally.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is at the center of investor attention with a highly anticipated regulatory decision for its Cushing's syndrome drug, relacorilant, prompting intense community debate and significant trading volume. Traders are closely watching for an approval or a potential Complete Response Letter, weighing recent sector approvals against CORT's price action and broader pipeline, including its ovarian cancer program, which fuels long-term bullish sentiment despite short-term uncertainty.

Themes ETF Trust - Leverage Shares 2X Long UNH Daily ETF

Leverage Shares 2X Long UNH Daily ETF

UNHG is trending amid widespread investor frustration over a significant price drop that appears decoupled from the performance of its underlying asset, UNH. The community is actively discussing a recent dividend event, which many perceive as fund manipulation or unusual decay rather than a true payout, raising serious concerns about the leveraged ETF's tracking accuracy. This has fueled a broader debate on the legitimacy and reliability of this relatively new 2x leveraged offering, with many advising caution against long-term positions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CARL Launches Aprevo Cervical Platform for Personalized Spine Surgery

Carlsmed launches personalized aprevo cervical platform with early cases and new reimbursement support driving momentum in spine surgery.

Carlsmed (NASDAQ:CARL) Raised to Hold at Wall Street Zen

Wall Street Zen upgraded Carlsmed from a "sell" rating to a "hold" rating in a report on Saturday...

Truist Financial Reaffirms Buy Rating for Carlsmed (NASDAQ:CARL)

Truist Financial reissued a "buy" rating and issued a $20.00 price objective (up previously from $18.00) on shares of Carlsmed in a research note on Friday...

Carlsmed (NASDAQ:CARL) Announces Earnings Results, Beats Expectations By $0.05 EPS

Carlsmed (NASDAQ:CARL - Get Free Report) posted its earnings results on Thursday. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.05...

Goldman Sachs has started coverage of Carlsmed with a ‘Buy’ rating and a $19 price target, suggesting about 35% upside from recent levels.The research firm’s&nbsp;analyst David Roman said the firm sees “meaningful upside” for the stock thanks to Carlsmed’s differentiated technology platform and asset-light business model,&nbsp;the Fly reported.He pointed to the company’s&nbsp;salesforce expansion, its planned 2026 launch in cervical spine procedures, and a steady flow of new clinical data as important revenue drivers.The call comes after several recent milestones. Earlier this month, the Centers for Medicare &amp; Medicaid Services (CMS) granted New Technology Add-On Payment (NTAP) reimbursement for cervical fusion procedures using Carlsmed’s aprevo implants.&nbsp;Starting&nbsp;in&nbsp;October, through the NTAP program, hospitals performing these procedures will be eligible for up to an additional $21,125 in reimbursement on top of standard payments.Carlsmed also reported the first cervical procedure with its aprevo device in July at UC San Diego Health, showing progress toward a U.S. launch targeted for 2026. The company’s technology is already approved for lumbar fusion surgery and uses AI-driven planning tools to design personalized implants for patients.The company had its initial public offering on July 23, raising $100.5 million at an IPO price of $15 per share. The shares dropped 3.3% on the first day of trading, closing at $14.50, valuing the company at about $384 million.&nbsp;Since then,&nbsp;<a href="https://stocktwits.com/symbol/CARL">Carlsmed’s shares</a>&nbsp;have fallen&nbsp;6.3% year-to-date. On Friday, the stock closed 2.7% lower at $13.58 before ticking up 0.5% after hours to $13.65.Carlsmed, founded in 2018, has drawn backing from B Capital Group and US Venture Partners, which together own nearly half the company. Co-founder and Chief Executive Michael Cordonnier holds a smaller stake.&nbsp;In the first quarter of 2025, the company lost $5.7 million on $10.2 million in revenue, compared with a loss of $5.4 million on $5.1 million in revenue a year earlier.On Stocktwits, retail sentiment for Carlsmed was ‘bearish’ by late Sunday, worsening from the ‘neutral’ mood seen a day ago, amid ‘normal’ message volume.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Goldman Sachs has started coverage of Carlsmed (CARL) with a ‘Buy’ rating and a $19 price target. (Photo credit: Getty Images)

Carlsmed Stock Down 6% Since IPO But Goldman Bullish And Predicts 35% Upside Potential — Retail Traders Stay Bearish

The company’s July IPO raised $100.5 million but shares have slipped since, closing Friday at $13.58 before edging up in after-hours trade.

Equity

Carlsmed, Inc. engages in the development of AI based technology solutions to the medical industry. Its solutions are utilized as an information database for surgeons using traditional surgical techniques. The company was founded by Mike Cordonnier and Niall Casey and is headquartered in Carlsbad, CA.

CARL
Carlsmed Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CARL News

CARLCarlsmed Inc